Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > News out
View:
Post by Lesalpes29 on Mar 31, 2022 7:17am

News out

https://stockhouse.com/news/press-releases/2022/03/31/oncolytics-biotech-xae-provides-positive-safety-update-on-the-third-line
Comment by canadafan on Mar 31, 2022 9:14am
ONC is in trials with 4 of the top ten pharms in the wolrd. Being Rcohe, Pfizer,Merck, B.M.S & Merck also a saller, tey large Incyte
Comment by fox7mf on Mar 31, 2022 9:53am
Great...will any of those 4 partner with or better yet purchase Onc or will they continue to spend on biotechs seemingly nowhere near as advanced as Onc? Question: is it at all possible that Adlai takes a run at us? Do they have the means $$$?
Comment by Noteable on Mar 31, 2022 12:46pm
The positive safety run-in news in the new indication of metastatic colorectal cancer broadens the potential use in the treatment of multiple cancers and by so doing increases the number of potential global pharma suitors and others from Europe, the United States, Asia and China.  As stated in the PR, the "study's Data Safety Monitoring Board (DSMB) noted no safety concerns in these ...more  
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities